Health
Alphabet’s Verily to sell Granular insurance business to Elevance Health
Verily headquarters in San Bruno, California. Courtesy: Verily Verily is selling its stop-loss insurance subsidiary, Granular Insurance Company, to the insurance provider Elevance Health, the Alphabet health tech company confirmed to CNBC on Thursday. Verily is one of Google’s sister companies and operates within Alphabet’s “Other Bets” category. The Granular sale is the latest in […]
Read More
Bristol Myers’ stock decline in response to weak guidance is a gift to investors
Bristol Myers Squibb on Thursday reported better-than-expected quarterly results, but weak guidance for 2025 sent shares lower. Jim Cramer’s faith in the drugmaker is unshaken. Revenue in the fourth quarter rose 8% year over year to $12.34 billion, well ahead of the $11.57 billion consensus, according to analysts’ estimates compiled by LSEG. Adjusted earnings per […]
Read More
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
The Eli Lilly & Co. logo at the company’s Digital Health Innovation Hub facility in Singapore, on Thursday, Nov. 14, 2024. Ore Huiying | Bloomberg | Getty Images Eli Lilly on Thursday said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide later this year, which is a […]
Read More
Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars
The Lilly Biotechnology Center in San Diego, California, on March 1, 2023. Mike Blake | Reuters Eli Lilly on Thursday reported mixed results for the fourth quarter as sales of its blockbuster weight loss and diabetes drugs soared but it saw lower realized prices. The figures were consistent with the preliminary results Eli Lilly shared […]
Read More
Novo Nordisk CEO says he’s confident about Wegovy supply, next-generation weight loss drugs
It’s been a rocky few months for Novo Nordisk. Prescription data from IQVIA suggests Novo’s obesity drug Wegovy is losing ground to rival Zepbound from Eli Lilly. Wegovy’s potential successor, CagriSema, came up short of investor expectations in a closely watched Phase 3 trial. Novo’s stock has fallen more than 20% over the last year, […]
Read More
Teladoc Health to acquire Catapult Health in $65 million deal
Pavlo Gonchar | Lightrocket | Getty Images Teladoc Health on Wednesday announced it will acquire the preventative care company Catapult Health in an all-cash deal for $65 million. Catapult offers an at-home wellness exam that allows members to check their blood pressure, collect a blood sample, log other screening information and meet virtually with a […]
Read More
Healthy Returns: Why people quit weight loss, diabetes drugs within one year
Packages of weight loss drugs Wegovy, Ozempic and Mounjaro. Picture Alliance | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Happy Tuesday! Most people quit a highly popular class of weight loss and […]
Read More
We’re making 4 trades, including an exit and an initiation, to reduce our tariff risk
Looking to reduce our exposure to tariffs and China, we’re making changes in the portfolio. We’re exiting our position in Stanley Black & Decker , selling our remaining 510 shares at roughly $86.79 each. We’re buying 50 shares of Home Depot at roughly $409.60. Following the trade, Jim Cramer’s Charitable Trust will own 300 shares […]
Read More
Senate panel advances RFK Jr.’s nomination to be health secretary
Robert F. Kennedy Jr., U.S. President Trump’s nominee to be secretary of Health and Human Services, testifies before a Senate Health, Education, Labor, and Pensions (HELP) Committee confirmation hearing on Capitol Hill in Washington, U.S., January 30, 2025. Nathan Howard | Reuters Robert F. Kennedy Jr. cleared a key hurdle Tuesday after a Senate panel […]
Read More
Pfizer tops earnings estimates as Covid product sales beat expectations and cost cuts pay off
Albert Bourla, chairman and CEO of Pfizer, speaks at The Wall Street Journal’s Future of Everything Festival in New York City, U.S., May 22, 2024. Andrew Kelly | Reuters Pfizer on Tuesday reported fourth-quarter earnings and revenue that beat estimates as sales of the company’s Covid products topped expectations and its broad cost-cutting efforts took […]
Read More